Summary
This 10-Q filing for Alnylam Pharmaceuticals, Inc. (ALNY) as of May 16, 2005, provides an unaudited look at the company's financial position and operational performance for the quarter ended March 31, 2005. As a development-stage biotechnology company, investors should focus on the company's cash burn, its progress in research and development, and its overall financial health. The filing details the company's balance sheet, statements of operations and comprehensive loss, and cash flows, offering insights into its ability to fund its ongoing operations and clinical trials.
Key Highlights
- 1Alnylam Pharmaceuticals, Inc. is operating as a development-stage biotechnology company, with its primary activities focused on research and development.
- 2The filing includes unaudited interim consolidated financial statements for the periods ended March 31, 2005, and March 31, 2004, allowing for a year-over-year comparison of performance.
- 3Key financial statements presented are the Balance Sheets, Statements of Operations and Comprehensive Loss, and Statements of Cash Flows.
- 4The Management's Discussion and Analysis (MD&A) section will provide crucial insights into the company's financial condition and the factors driving its results of operations.
- 5Investors should pay close attention to the cash flow statement to understand the company's cash burn rate and its ability to fund its R&D activities.
- 6The filing also includes quantitative and qualitative disclosures about market risk, which could impact the company's financial performance.
- 7Disclosure of unregistered sales of equity securities and use of proceeds, if any, will be important for understanding potential dilution or capital raising activities.
Frequently Asked Questions
Based on this 10-Q filing, Alnylam Pharmaceuticals, Inc. is a development-stage biotechnology company whose primary focus is on research and development activities, likely centered around its proprietary RNA interference (RNAi) therapeutics.
The key financial statements provided are the unaudited interim consolidated balance sheets as of March 31, 2005, and December 31, 2004, the unaudited interim consolidated statements of operations and comprehensive loss for the three months ended March 31, 2005 and 2004, and the unaudited interim consolidated statements of cash flows for the three months ended March 31, 2005 and 2004.
For a development-stage biotechnology company, investors should be most concerned with the company's cash burn rate, as detailed in the Statement of Cash Flows, and its overall liquidity as shown on the Balance Sheet, to understand its ability to fund ongoing research and development initiatives until it reaches commercialization or secures further funding.
More detailed information about the company's financial condition and results of operations can be found in 'Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations'.